Revenue: US$9.18m (up 71% from 3Q 2023). Net loss: US$6.41m (down from US$136.1k profit in 3Q 2023). US$0.21 loss per share ...
Key Insights Significantly high institutional ownership implies Ventyx Biosciences' stock price is sensitive to ...